CH649924A5 - Reduktionsmaterial zur reduktion von technetium unter bildung eines technetiummarkierten liganden. - Google Patents
Reduktionsmaterial zur reduktion von technetium unter bildung eines technetiummarkierten liganden. Download PDFInfo
- Publication number
- CH649924A5 CH649924A5 CH4896/79A CH489679A CH649924A5 CH 649924 A5 CH649924 A5 CH 649924A5 CH 4896/79 A CH4896/79 A CH 4896/79A CH 489679 A CH489679 A CH 489679A CH 649924 A5 CH649924 A5 CH 649924A5
- Authority
- CH
- Switzerland
- Prior art keywords
- ligand
- technetium
- labeled
- reducing
- reducing agent
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims description 118
- 239000000463 material Substances 0.000 title claims description 59
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 title claims description 42
- 229910052713 technetium Inorganic materials 0.000 title claims description 41
- 230000009467 reduction Effects 0.000 title claims description 20
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 80
- 239000000758 substrate Substances 0.000 claims description 41
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 29
- 229940056501 technetium 99m Drugs 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- 239000012217 radiopharmaceutical Substances 0.000 claims description 18
- 239000011521 glass Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000007254 oxidation reaction Methods 0.000 claims description 14
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 13
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000003647 oxidation Effects 0.000 claims description 12
- -1 N- (2,6-dimethyliodylphenylcarbamoylmethyl) -iminodiacetic acid Chemical compound 0.000 claims description 9
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 4
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 229940050410 gluconate Drugs 0.000 claims description 4
- 229920005615 natural polymer Polymers 0.000 claims description 4
- 229960003540 oxyquinoline Drugs 0.000 claims description 4
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 3
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 3
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 108010074605 gamma-Globulins Proteins 0.000 claims description 3
- 229940102859 methylene diphosphonate Drugs 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 235000002949 phytic acid Nutrition 0.000 claims description 3
- XFQYOFLFNKCHLG-UHFFFAOYSA-N 3-acetyl-6-bromochromen-2-one Chemical compound BrC1=CC=C2OC(=O)C(C(=O)C)=CC2=C1 XFQYOFLFNKCHLG-UHFFFAOYSA-N 0.000 claims description 2
- HWZUDASOMGNLSM-UHFFFAOYSA-N O=P1OCOP(=O)O1 Chemical compound O=P1OCOP(=O)O1 HWZUDASOMGNLSM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- XSYSSUAGVNOMCE-UHFFFAOYSA-N 2-[[2-(4-butylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CCCCC1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C=C1 XSYSSUAGVNOMCE-UHFFFAOYSA-N 0.000 claims 1
- HJGKERBNCJCPFQ-UHFFFAOYSA-N 4-(4-butylanilino)-2-(carboxymethylamino)-4-oxobutanoic acid Chemical compound CCCCc1ccc(NC(=O)CC(NCC(O)=O)C(O)=O)cc1 HJGKERBNCJCPFQ-UHFFFAOYSA-N 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- HAJDENBPCFUZJU-UHFFFAOYSA-N O(CC)P(=O)(O)OP(=O)O Chemical compound O(CC)P(=O)(O)OP(=O)O HAJDENBPCFUZJU-UHFFFAOYSA-N 0.000 claims 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 claims 1
- UDUSOMRJOPCWHT-UHFFFAOYSA-N disofenin Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O UDUSOMRJOPCWHT-UHFFFAOYSA-N 0.000 claims 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000000047 product Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 17
- 239000011324 bead Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000011150 stannous chloride Nutrition 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 239000013522 chelant Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZPBLNADJHWHOEP-UHFFFAOYSA-N 5-benzamido-n-(4-chlorophenyl)-3-methyl-1,2-thiazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1NC(=O)C=1C(C)=NSC=1NC(=O)C1=CC=CC=C1 ZPBLNADJHWHOEP-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- DJQJFMSHHYAZJD-UHFFFAOYSA-N lidofenin Chemical compound CC1=CC=CC(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O DJQJFMSHHYAZJD-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- QGJDXUIYIUGQGO-UHFFFAOYSA-N 1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)N1CCCC1C(O)=O QGJDXUIYIUGQGO-UHFFFAOYSA-N 0.000 description 2
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229950009740 molybdenum mo-99 Drugs 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229910052845 zircon Inorganic materials 0.000 description 2
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 2
- UUGRFRITTVBJHJ-UHFFFAOYSA-N 1,3,6,8,10,13,16,19-octazabicyclo[6.6.6]icosane Chemical compound C1NCCNCN2CNCCNCN1CNCCNC2 UUGRFRITTVBJHJ-UHFFFAOYSA-N 0.000 description 1
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
- YKFJKIOXUFGTFV-UHFFFAOYSA-N 2-[[2-amino-1-(4-butylphenyl)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CCCCC1=CC=C(C(N(CC(O)=O)CC(O)=O)C(N)=O)C=C1 YKFJKIOXUFGTFV-UHFFFAOYSA-N 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001211977 Bida Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 238000003831 Wilkinson decarbonylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004038 corrins Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940007163 stannous tartrate Drugs 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G99/00—Subject matter not provided for in other groups of this subclass
- C01G99/006—Compounds containing a metal not provided for elsewhere in this subclass, with or without oxygen or hydrogen, and containing two or more other elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/909,385 US4272503A (en) | 1978-05-25 | 1978-05-25 | Reductant composition for technetium-99m and method for making technetium-99m labelled ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH649924A5 true CH649924A5 (de) | 1985-06-28 |
Family
ID=25427158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4896/79A CH649924A5 (de) | 1978-05-25 | 1979-05-25 | Reduktionsmaterial zur reduktion von technetium unter bildung eines technetiummarkierten liganden. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4272503A (cg-RX-API-DMAC7.html) |
| JP (2) | JPS54160305A (cg-RX-API-DMAC7.html) |
| BE (1) | BE876562A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1111765A (cg-RX-API-DMAC7.html) |
| CH (1) | CH649924A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2920770A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2430236A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2023327B (cg-RX-API-DMAC7.html) |
| NL (1) | NL7904059A (cg-RX-API-DMAC7.html) |
| SE (1) | SE7904316L (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
| US4406876A (en) * | 1980-10-14 | 1983-09-27 | Research Foundation Of The State Univ. Of New York | Sulfur free small-particle production of technetium sulfur colloid |
| US4436718A (en) | 1981-10-13 | 1984-03-13 | Pierce Chemical Company | Iodinating reagent |
| ES8404857A1 (es) * | 1981-10-27 | 1984-05-16 | Hybritech Inc | Un procedimiento para preparar un anticuerpo monoclonal para un antigeno asociado a un tumor. |
| DE3237573A1 (de) * | 1982-10-09 | 1984-04-12 | Hoechst Ag, 6230 Frankfurt | Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung |
| US4574079A (en) * | 1983-05-27 | 1986-03-04 | Gavras Haralambos P | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites |
| EP0163701A1 (en) * | 1983-12-06 | 1985-12-11 | The Royal Melbourne Hospital | PREPARATION OF RADIOPHARMACEUTICALS BASED ON TECHNETIUM-99m/ |
| USRE38435E1 (en) * | 1983-12-28 | 2004-02-24 | Daicel Chemical Industries, Ltd. | Separating agent |
| US4707352A (en) * | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group |
| US5164175A (en) * | 1986-12-10 | 1992-11-17 | Hoechst Aktiengesellschaft | Diagnostic aid containing an organ-specific substance labeled with technetium-99m |
| US5059541A (en) * | 1988-04-29 | 1991-10-22 | Neorx Corporation | Minimal derivatization of proteins |
| US5208007A (en) * | 1988-11-22 | 1993-05-04 | Board Of Regents Of The University Of Oklahoma | Isotopic tracer composition and method for making and using same |
| US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
| MXPA94002323A (es) * | 1993-03-31 | 2002-06-18 | Mallinckrodt Medical Inc | Formulaciones radiofarmaceuticas que tienen reductores no estanosos. |
| US5608110A (en) * | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
| ATE334704T1 (de) * | 1993-11-16 | 2006-08-15 | Bracco Int Bv | Immobilisiertes markierungsverfahren |
| US5774782A (en) * | 1996-05-22 | 1998-06-30 | Lockheed Martin Energy Systems, Inc. | Technetium-99m generator system |
| WO2002082051A2 (en) * | 2001-01-17 | 2002-10-17 | Tubbs Kemmons A | An integrated high throughput system for the analysis of biomolecules |
| US7799526B2 (en) * | 2002-11-21 | 2010-09-21 | The University Of North Carolina At Chapel Hill | Phosphoprotein detection reagent and methods of making and using the same |
| GB0804406D0 (en) * | 2008-03-10 | 2008-04-16 | Univ Zuerich | Metal complexes |
| JP5829919B2 (ja) * | 2010-02-05 | 2015-12-09 | ナミックス株式会社 | 金属導電性ペースト用の還元剤組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784453A (en) * | 1970-12-16 | 1974-01-08 | H Dworkin | Process and apparatus for making radioactive labeled protein material |
| DE2166643A1 (de) * | 1971-03-25 | 1975-01-30 | Minnesota Mining & Mfg | Verfahren zum radioaktiven kennzeichnen von pharmazeutisch unbedenklichen mikropartikeln |
| DE2127809A1 (en) * | 1971-06-01 | 1972-12-14 | Kort, Waiter, Dr , 1000 Berlin | Radioactive technetium-iron complex - for scintigraphy of organs and blood vessels |
| US3725295A (en) * | 1971-07-20 | 1973-04-03 | Atomic Energy Commission | Technetium labeling |
| US3873680A (en) * | 1972-08-30 | 1975-03-25 | Minnesota Mining & Mfg | Mercaptan and thioketal complexes of technetium 99M for diagnostic scanning |
| US3868383A (en) * | 1973-04-23 | 1975-02-25 | Lilly Co Eli | Process for preparing 5-({60 -cyanobenzylidene) oxazolidine-2, 4-diones |
| CA1070695A (en) * | 1975-09-02 | 1980-01-29 | Michael D. Loberg | Iminodiacetic acid pharmaceutical |
| DE2543351A1 (de) * | 1975-09-29 | 1977-04-07 | Henkel & Cie Gmbh | Praeparate zur herstellung von 99m technetum-radiodiagnostika |
-
1978
- 1978-05-25 US US05/909,385 patent/US4272503A/en not_active Expired - Lifetime
-
1979
- 1979-01-15 CA CA319,663A patent/CA1111765A/en not_active Expired
- 1979-04-13 JP JP4522679A patent/JPS54160305A/ja active Pending
- 1979-05-16 SE SE7904316A patent/SE7904316L/xx not_active Application Discontinuation
- 1979-05-22 DE DE19792920770 patent/DE2920770A1/de not_active Ceased
- 1979-05-23 GB GB7917979A patent/GB2023327B/en not_active Expired
- 1979-05-23 NL NL7904059AA patent/NL7904059A/xx not_active Application Discontinuation
- 1979-05-23 FR FR7913264A patent/FR2430236A1/fr active Granted
- 1979-05-25 CH CH4896/79A patent/CH649924A5/de not_active IP Right Cessation
- 1979-05-25 BE BE0/195405A patent/BE876562A/xx not_active IP Right Cessation
-
1982
- 1982-10-15 JP JP57181234A patent/JPS58146514A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US4272503A (en) | 1981-06-09 |
| GB2023327B (en) | 1982-08-25 |
| GB2023327A (en) | 1979-12-28 |
| JPS58146514A (ja) | 1983-09-01 |
| SE7904316L (sv) | 1979-11-26 |
| FR2430236A1 (fr) | 1980-02-01 |
| JPS54160305A (en) | 1979-12-19 |
| DE2920770A1 (de) | 1979-11-29 |
| CA1111765A (en) | 1981-11-03 |
| FR2430236B1 (cg-RX-API-DMAC7.html) | 1983-05-13 |
| NL7904059A (nl) | 1979-11-27 |
| BE876562A (fr) | 1979-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH649924A5 (de) | Reduktionsmaterial zur reduktion von technetium unter bildung eines technetiummarkierten liganden. | |
| DE69030025T2 (de) | Verfahren zur Markierung von Proteinen mit Technetium/Rhenium | |
| DE3850497T2 (de) | Methode zur markierung von antikörpern mit einem metallion. | |
| DE69032742T2 (de) | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium | |
| DE69315565T2 (de) | Konjugate von biotin und deferoxamine für radio-immuntherapie und -immunbilderzeugung | |
| EP0271806B1 (de) | Verfahren zur Herstellung einer mit Technetium-99m-markierten organspezifischen Substanz | |
| DE2538388C3 (de) | Verfahren zur Herstellung eines stabilen, nicht-radioaktiven Trägermaterials für mit radioaktiven Elementen markierte Diagnosemittel und seine Verwendung für mit Tc-99m-markierte Diagnosemittel | |
| DE69131881T2 (de) | 99mTc MARKIERTE LIPOSOMEN | |
| DE2543349A1 (de) | Praeparate zur herstellung von hoch 99m technetium-radiodiagnostika | |
| DE3014721C2 (cg-RX-API-DMAC7.html) | ||
| DE2536713A1 (de) | Verfahren zur bestimmung von vitamin-b-12 mit radioisotopen | |
| DE2322758A1 (de) | Verfahren zur herstellung von injizierbaren praeparaten des tc99m und/oder in113m und vorrichtung zur durchfuehrung des verfahrens | |
| DE3320560C2 (cg-RX-API-DMAC7.html) | ||
| DE69033953T2 (de) | Kolloidale radiomarkierte zusammensetzungen, deren anwendung und verfahren zu deren herstellung | |
| CH622705A5 (cg-RX-API-DMAC7.html) | ||
| DE2534985C2 (cg-RX-API-DMAC7.html) | ||
| DE2947500A1 (de) | Radiojodierte (omega) -phenylfettsaeuren, ihre herstellung und praeparate zur szintigraphischen untersuchung desherzmuskels und der leber | |
| EP0772633B1 (de) | Komplexverbindungen zur diagnose von gefässerkrankungen | |
| DE2419310C3 (de) | Verwendung von Tc-99m-Komplexen | |
| US4042676A (en) | Technetium-99m labeled radiodiagnostic agents for liver and bone marrow scanning and method of preparation | |
| DE2327870C2 (de) | Verfahren zur Herstellung eines mit 99↑m↑ Tc markierten Phosphat-Zinn-Komplexes zur Szintigraphie | |
| CH624847A5 (cg-RX-API-DMAC7.html) | ||
| CH630261A5 (de) | Verfahren und ampulle zur herstellung von radiopharmazeutika. | |
| EP0335296B1 (de) | Tc-99m-w-Alkylphosphinico-1-hydroxyalkan-1,1-diphosphonate enthaltende Präparate zur Knochenszintigraphie sowie Verfahren zur Herstellung dieser Präparate | |
| DE2424496C3 (de) | Zusammensetzung zur Herstellung eines Mittels zur scintigraphischen Knochenabtastung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: THE DU PONT MERCK PHARMACEUTICAL COMPANY |
|
| PL | Patent ceased | ||
| PL | Patent ceased |